香港六合彩开奖结果

Vol. 23 No. 1 (2024)
Literature Review

Piperacillin-Tazobactam: update for clinical use

pdf
  • Alice Rezende Correa e Castro Costa,
  • Andr茅ia Patr铆cia Gomes,
  • Eduardo Vin铆cius Vieira Varej茫o,
  • Romario Brunes Will,
  • Walter Tavares,
  • Luiz Alberto Santana,
  • Rodrigo Siqueira-Batista
Rodrigo Siqueira-Batista
Universidade Federal de Vi莽osa
DOI:

Published 2024-08-21

Keywords

  • Anti-Bacterial Agents; Piperacillin, Tazobactam Drug Combination; beta-Lactams

How to Cite

1.
Rezende Correa e Castro Costa A, Gomes AP, Vieira Varej茫o EV, Will RB, Tavares W, Santana LA, Siqueira-Batista R. Piperacillin-Tazobactam: update for clinical use. BJHBS [Internet]. 2024 Aug. 21 [cited 2024 Oct. 12];23(1). Available from: /bjhbs/article/view/165

Copyright (c) 2024 香港六合彩开奖结果

This work is licensed under a .

Crossref
Scopus

Abstract

Introduction: Piperacillin-tazobactam, a broad-spectrum penicillin, represents a crucial option in the treatment of infections, especially in critically ill patients who exhibit high rates of resistance to various antimicrobial agents. It is of paramount importance to understand this medication and its updates regarding its clinical use to inform precise therapeutic choices aimed at optimizing patient care. Objective: To describe the main pharmacological and therapeutic aspects of piperacillin-tazobactam, highlighting its clinical application and updates related to its use. Methods: A narrative review of the literature was conducted to provide an update on the most relevant aspects related to piperacillin-tazobactam, including (1) a brief history; (2) chemical structure; (3) mechanism of action; (4) resistance mechanisms; (5) spectrum; (6) major clinical uses; and (7) adverse effects. Results: The safe use of piperacillin-tazobactam necessitates rapid testing for antimicrobial resistance patterns, discouraging its empirical use in cases of ESBL-producing microorganisms. In patients undergoing renal replacement therapy, it is crucial to establish antibiotic goals promptly. For critically ill patients, monitoring pharmacodynamic and pharmacokinetic variability is essential. Conclusion: Piperacillin-tazobactam remains a vital drug in the management of critically ill patients, requiring constant updates. Furthermore, there is a need for further studies, especially concerning its continuous use and the selection of alternatives to carbapenem-resistant medications.

pdf

Metrics

Metrics Loading ...

References

  1. Bennet JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennet鈥檚 Principles and Practice of Infectious Diseases . 9th ed. Philadelphia: Elsevier; 2020
  2. Tavares W. Antibi贸ticos e Quimioter谩picos para o cl铆nico. 4. ed. S茫o Paulo: Atheneu; 2020.
  3. Pilmis B, Jullien V, Tabah A, et al. Piperacillin鈥搕azobactam as alternative to carbapenems for ICU patients. Annals of Intensive Care [Internet]. 2017 Nov 10;7. Available from:
  4. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin鈥搕azobactam: a 尾-lactam/尾-lactamase inhibitor combination. Expert Review of Anti-infective Therapy. 2007 Jun;5(3):365鈥�83.
  5. Goodman LS, Gilman AG, Brunton LL, et al. As Bases Farmacol贸gicas da Terap锚utica de Goodman & Gilman. Porto Alegre (Rs): AMGH; 2012.
  6. Selig DJ, DeLuca JP, Chung KK, et al. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini鈥恟eview and population pharmacokinetic analysis. Journal of Clinical Pharmacy and Therapeutics. 2022 Mar 29;47(8):1091鈥�102.
  7. Kornmehl H, Gorouhi F, Konia T, et al. Generalized fixed drug eruption to piperacillin/tazobactam and review of literature. Dermatology Online Journal [Internet]. 2018 Apr 15 [cited 2023 Nov 3];24(4):13030/qt8cr714g5. Available from:
  8. Tipos de Revis茫o de Literatura [Internet]. 2015 [cited 2023 Nov 3]. Available from:
  9. Elias C de SR, Silva LA da, Martins MT de SL, Ramos NAP, Souza M das GG de, Hip贸lito RL. Quando chega o fim?: uma revis茫o narrativa sobre terminalidade do per铆odo escolar para alunos deficientes mentais. SMAD Revista eletr么nica sa煤de mental 谩lcool e drogas [Internet]. 2012 Apr 1[cited 2023 Nov 3];8(1):48鈥�53. Available from:
  10. Rother ET. Systematic literature review X narrative review. Acta Paulista de Enfermagem [Internet]. 2007 Jun;20(2):v鈥搗i. Available from:
  11. Vardanyan RS, Hruby VJ. Synthesis of essential drugs. Amsterdam: Elsevier Science; 2006.
  12. Neu HC. 尾-Lactam Antibiotics: Structural Relationships Affecting in Vitro Activity and Pharmacologic Properties. Clinical Infectious Diseases. 1986 Jul 1;8(Supplement_3):S237鈥�59.
  13. Fernandes R, Amador P, Prud锚ncio C. 尾-Lactams: chemical structure mode of action and mechanisms of resistence. Reviews in Medical Microbiology. 2013 Jan;24(1):7鈥�17.
  14. Solomons TWWG, Fryhle CB. Qu铆mica Org芒nica. 10th ed. LTC; 2013.
  15. De Rosa M, Verdino A, Soriente A, Marabotti A. The Odd Couple(s): An Overview of Beta-Lactam Antibiotics Bearing More Than One Pharmacophoric Group. International Journal of Molecular Sciences. 2021 Jan 9;22(2):617.
  16. Siqueira-Batista R, Alves MMR, Lara MAG, et al. Penicilinas: atualiza莽茫o para a pr谩tica cl铆nica. Revista M茅dica de Minas Gerais [Internet]. 2023 Aug 31;33. Available from:
  17. Gage-Brown A, George C, Maleki J, et al. Is Piperacillin-Tazobactam an Appropriate Empirical Agent for Hospital-Acquired Sepsis and Community-Acquired Septic Shock of Unknown Origin in Australia? Healthcare. 2022 May 5;10(5):851.
  18. Schuetz AN, Reyes S, Tamma PD. Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms. Caliendo AM, editor. Journal of Clinical Microbiology. 2018 Mar;56(3).
  19. Jorge PRF, Pimenta JP, Brito CS de, et al. Pseudomonas aeruginosa resistente aos carbapen锚micos produtor de NDM-1. Revista M茅dica de Minas Gerais [Internet]. 2023 Aug 31;33(1). Available from:
  20. Rabiei MM, Asadi K, Shokouhi S, et al. Antipseudomonal 尾-Lactams Resistance in Iran. International Journal of Microbiology [Internet]. 2020 Dec 16;2020:e8818315. Available from:
  21. El-Haffaf I, Caissy JA, Marsot A. Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses. Clinical Pharmacokinetics. 2021 Apr 20;60(7):855鈥�75.